Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Scholar Rock Holding Corp. SRRK

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-377.9M
$-300.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -377.9
-150M-300M
2017202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2022 · Operating -404.8% · Net -405.2%
-200%-400%-600%
201720212025
ROE
FY2025 · ROE -123.1%
-50%-100%
201720212025
Three returns, three denominators.

Each USD of equity lost 123 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -300.6
-150M-300M
201720212025

Total assetsUSD 404.3M
EquityUSD 245.5M
CashUSD 323.5M
Gross debtUSD 99.7M
Net debtUSD -223.8M
Current ratio6.95×

The company holds more cash than debt.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
SRRK, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.0◌◌0.00.00.00.00.0◌
Operating income $B−0.4−0.3−0.2−0.1−0.1−0.1−0.1−0.1−0.0
EBITDA $B◌◌◌◌◌◌◌◌◌
Income tax $B◌◌◌◌◌◌◌◌◌
Net income $B−0.4−0.2−0.2−0.1−0.1−0.1−0.1−0.0−0.0
Free cash flow $B−0.3−0.2−0.1−0.1−0.1−0.1−0.10.0−0.0
EPS, diluted $−3.29−2.47−1.99−2.26−3.59−2.81−1.85−3.15−15.30
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %−123.1−82.9−68.3−62.2−60.9−46.3−46.5——
Shares out B0.110.090.080.050.040.030.030.030.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 36 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 10 checks were skipped: EPS is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image